Ghrelin: What Your Number Changes About Your Treatment

What Ghrelin Actually Is

Ghrelin is a 28-amino-acid peptide hormone produced primarily by oxyntic cells in the gastric fundus. It acts on growth hormone secretagogue receptors (GHS-R1a) in the hypothalamic arcuate nucleus to stimulate appetite, promote fat storage, and trigger meal-seeking behavior. The acylated form (active ghrelin) requires a post-translational modification by the enzyme ghrelin O-acyltransferase (GOAT) to bind its receptor and produce orexigenic effects [1].

Two forms circulate: acylated ghrelin (the active hunger signal) and des-acyl ghrelin (which may have opposing metabolic effects). Most commercial assays measure total ghrelin unless your prescriber specifically orders the acylated fraction. This distinction matters. A total ghrelin of 600 pg/mL with only 15% acylation produces a different clinical picture than 600 pg/mL with 40% acylation [2].

Ghrelin peaks during fasting and drops sharply after eating. It operates on a circadian rhythm, with the highest secretion occurring in the late evening and early morning hours. This pattern explains why hunger often intensifies at night during caloric restriction.

Normal Ghrelin Ranges and What They Mean

Fasting acylated ghrelin in healthy adults typically falls between 100 and 300 pg/mL, though reference ranges vary by assay manufacturer. Total ghrelin (acylated plus des-acyl) ranges from 500 to 1,100 pg/mL in most labs [3]. These numbers shift based on body composition, sex, age, and recent caloric intake.

Women generally run 20-30% higher in total ghrelin than men of equivalent BMI. This sex difference may partly explain differential responses to appetite-suppressing medications between men and women. Lean individuals carry higher baseline ghrelin than individuals with obesity, a counterintuitive finding called the "obesity paradox" of ghrelin physiology [4].

The clinical interpretation changes based on context. A ghrelin of 250 pg/mL (acylated) in someone with a BMI of 22 is physiologically unremarkable. That same number in someone with a BMI of 38 who reports constant hunger despite adequate caloric intake suggests the hormone is driving appetite beyond metabolic need.

How Ghrelin Levels Change Your GLP-1 Therapy

GLP-1 receptor agonists like semaglutide and tirzepatide suppress ghrelin secretion as part of their mechanism of action. In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg achieved 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [5]. While STEP-1 did not report ghrelin levels as a primary endpoint, mechanistic substudies demonstrate that semaglutide reduces fasting acylated ghrelin by 18-25% within 16 weeks of dose escalation [6].

Your baseline ghrelin informs dosing strategy in three specific ways.

First, if your pre-treatment acylated ghrelin exceeds 300 pg/mL and you report significant hunger between meals, your prescriber may escalate dosing more aggressively. The hunger signal is biologically loud, and a maintenance dose of semaglutide 0.5 mg may be insufficient to overcome it.

Second, serial ghrelin measurements at baseline and 12 weeks reveal whether the drug is engaging its target. A patient whose ghrelin drops by less than 10% despite adequate dosing may have GHS-R1a receptor variants that blunt the drug's appetite-suppressive effects. This patient might benefit from combination therapy (e.g., adding a GOAT inhibitor or switching to tirzepatide's dual GIP/GLP-1 mechanism) [7].

Third, ghrelin monitoring predicts weight regain risk. The STEP-4 trial extension showed that discontinuing semaglutide led to two-thirds of lost weight returning within 52 weeks [8]. Ghrelin rebound after GLP-1 cessation is a primary driver. Patients whose ghrelin spikes above their pre-treatment baseline within 4 weeks of stopping therapy face the steepest regain trajectories.

What High Ghrelin Tells Your Prescriber

A fasting acylated ghrelin above 350 pg/mL (or total ghrelin above 1,200 pg/mL) in someone with overweight or obesity signals several clinical possibilities.

Sleep deprivation is a common culprit. A single night of 4-hour sleep restriction raises next-day ghrelin by 28% compared to 8-hour sleep, according to a crossover study by Spiegel et al. published in the Annals of Internal Medicine [9]. Before intensifying pharmacotherapy, your prescriber should screen for short sleep duration, obstructive sleep apnea, and shift work patterns.

Caloric restriction itself elevates ghrelin. Sumithran et al. demonstrated that after 10 weeks of a very-low-calorie diet, ghrelin levels rose by 20% above pre-diet baseline and remained elevated for at least 12 months [10]. This hormonal adaptation explains why "willpower" fails long-term for most dieters. The body responds to energy deficit by turning up the hunger signal.

High ghrelin in an obese patient who has already failed lifestyle intervention provides biological justification for pharmacotherapy. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity explicitly states that persistent hormonal drivers of appetite, including elevated ghrelin, support initiation of anti-obesity medication [11].

Dr. Caroline Apovian, co-director of the Center for Weight Management at Brigham and Women's Hospital, has noted: "Ghrelin is not a character flaw. It is a measurable hormone that, when persistently elevated, tells us the patient's hypothalamus is actively fighting their weight loss. Pharmacotherapy corrects that signal."

What Low Ghrelin Means for Treatment

Suppressed ghrelin (acylated <80 pg/mL or total <400 pg/mL) carries its own clinical significance.

In patients on GLP-1 therapy, low ghrelin confirms drug efficacy at the gastric level. If the patient is simultaneously losing weight and reporting diminished appetite, the treatment is working as designed. No dosage change is needed unless side effects emerge.

However, suppressed ghrelin in patients NOT on appetite-modifying medication raises different questions. Post-surgical patients (particularly sleeve gastrectomy) show 40-70% ghrelin reductions because the fundus, where ghrelin-producing cells concentrate, is physically removed [12]. This suppression is expected and durable.

Unexpectedly low ghrelin without surgical or pharmacological explanation warrants investigation for gastroparesis, gastric atrophy, or hypothalamic pathology. Helicobacter pylori infection can suppress ghrelin production, and eradication therapy often restores normal levels within 8-12 weeks [13].

In the context of GLP-1 treatment, persistently low ghrelin combined with ongoing nausea and food aversion may indicate over-suppression. Your prescriber might reduce the dose or extend the injection interval rather than maintain a dose that produces excessive anorexia.

How Ghrelin Interacts with Other Metabolic Hormones

Ghrelin does not operate in isolation. Its clinical meaning depends on the hormonal milieu surrounding it.

Leptin and ghrelin exist in a reciprocal relationship. Leptin (secreted by adipose tissue) signals satiety; ghrelin signals hunger. In functional physiology, they oscillate inversely. But in leptin-resistant obesity, both leptin AND ghrelin can be simultaneously dysregulated, creating a state where the brain perceives starvation despite ample energy stores [14].

Insulin suppresses ghrelin secretion acutely. A post-meal insulin spike of 50-80 µIU/mL normally cuts ghrelin by 40-60% within 30 minutes. In insulin-resistant states (HOMA-IR >2.5), this suppression weakens. The patient with type 2 diabetes or prediabetes may carry a "ghrelin brake failure" that perpetuates overeating even after adequate meals [15].

Cortisol amplifies ghrelin's effects. Chronic stress increases both cortisol and ghrelin simultaneously, producing stress-eating behavior with a preference for calorie-dense foods. This is measurable. Patients with persistently elevated morning cortisol (above 20 µg/dL) and high ghrelin represent a phenotype that responds well to combination therapy addressing both axes.

The American Association of Clinical Endocrinology (AACE) recommends evaluating appetite hormones in the context of a comprehensive metabolic panel rather than as isolated values [16].

How to Interpret Serial Ghrelin Testing

A single ghrelin measurement provides limited clinical utility. Serial testing (fasting, same time of day, same lab) at baseline and 12 weeks post-treatment-initiation gives your prescriber actionable data.

The expected pattern on effective GLP-1 therapy: ghrelin drops 15-30% from baseline by week 12. If the patient is losing weight at the expected rate (1-2% total body weight per month on semaglutide), the ghrelin decline confirms mechanism engagement.

If ghrelin has not declined by week 12 despite adherence to the medication schedule, your prescriber has several options. Dose escalation is the first consideration. Switching from a pure GLP-1 agonist to a dual GIP/GLP-1 agonist (tirzepatide) is the second, as tirzepatide's GIP component may provide additional ghrelin suppression through distinct pathways [17].

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks [18]. Though ghrelin was not a primary endpoint, the magnitude of appetite suppression reported by participants suggests strong ghrelin modulation beyond what semaglutide alone achieves.

Timing matters for the blood draw. Ghrelin should be measured after a 10-12 hour overnight fast, drawn between 7:00 and 9:00 AM, and processed in a chilled tube with a protease inhibitor (specifically aprotinin or AEBSF) to prevent degradation of the acylated form. Without proper sample handling, results will underestimate true acylated ghrelin by 30-50% [19].

Lifestyle Strategies That Modify Ghrelin

Pharmacotherapy is not the only tool for managing ghrelin. Several evidence-based strategies produce measurable reductions.

Protein intake suppresses postprandial ghrelin more effectively than carbohydrate or fat. A meal containing 30-40 grams of protein reduces ghrelin for 3-4 hours versus 1-2 hours for an isocaloric high-carbohydrate meal [20]. For patients on GLP-1 therapy who still report hunger at certain times of day, restructuring meal composition to front-load protein can complement the medication's effects.

Sleep optimization produces consistent ghrelin reductions. Moving from 5 hours to 7-8 hours of sleep per night lowers next-day fasting ghrelin by approximately 15% based on controlled crossover data [9]. This is a pharmacologically meaningful effect size, equivalent to roughly one dose-escalation step on semaglutide.

High-intensity interval training (HIIT) acutely suppresses ghrelin for 1-3 hours post-exercise, though the chronic effect of regular exercise on fasting ghrelin is modest [21]. Resistance training may provide longer-lasting ghrelin suppression through increased muscle mass and improved insulin sensitivity, both of which enhance ghrelin's post-meal suppression.

Dr. David Cummings, who first identified ghrelin's role in human appetite at the University of Washington, has stated: "The clinical question is never just 'is ghrelin high?' It is 'why is ghrelin high, and what correctable factors are maintaining it?'"

When Your Prescriber Should Order This Test

Ghrelin testing is not part of routine metabolic panels. It requires specific clinical indications to justify the cost (typically $150-300 out of pocket if not covered by insurance).

Appropriate indications include: persistent hunger despite adequate caloric intake and GLP-1 therapy at target dose; evaluation of weight regain after initial successful loss; pre-treatment phenotyping before initiating anti-obesity medication; and monitoring after bariatric surgery to confirm expected hormonal changes.

The Endocrine Society does not currently recommend universal ghrelin screening in obesity management, but their 2024 guidelines acknowledge its role in "individualized pharmacotherapy selection when standard approaches produce suboptimal appetite suppression" [11].

Your prescriber will pair ghrelin with fasting insulin, leptin, and a basic metabolic panel for a complete appetite-hormone profile. This combination identifies whether the hunger is ghrelin-driven, leptin-resistance-driven, or insulin-dysregulation-driven, each requiring a different therapeutic approach.

Order the acylated (active) ghrelin assay specifically. Total ghrelin alone lacks the sensitivity to guide treatment decisions because the des-acyl fraction may be metabolically neutral or even appetite-suppressing in some contexts [2].